• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Terns Pharmaceuticals Inc.

    6/7/24 8:30:01 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TERN alert in real time by email
    SC 13G 1 ea0207479-13gsoleus_terns.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Terns Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    880881107

    (CUSIP Number)

     

    June 6, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☒ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 880881107  

     

    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
    Soleus Capital Master Fund, L.P.
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐

    (b)  ☐

    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    3,341,120 (1)
    7 SOLE DISPOSITIVE POWER
    0
    8 SHARED DISPOSITIVE POWER
    3,341,120 (1) 

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    3,341,120 (1)
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐      
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.2% (2)
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    FI

     

    FOOTNOTES

     

    (1) The shares of common stock reported in this row are held by Soleus Capital Master Fund, L.P. (“Master Fund”). Soleus Capital, LLC (“Soleus Capital”) is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC (“SCG”) is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or for any other purpose, except to the extent of their respective pecuniary interests therein.

     

    (2) This percentage is calculated based upon 64,677,145 shares of the common stock of the Issuer (“Common Stock”) outstanding as of May 3, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2024 filed with the Securities and Exchange Commission on May 13, 2024 (the “Form 10-Q”).

     

    2

     

     

    CUSIP No. 880881107  

     

    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
    Soleus Capital, LLC
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ☐

    (b) ☐

    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    3,341,120 (1)
    7 SOLE DISPOSITIVE POWER
    0
    8 SHARED DISPOSITIVE POWER
    3,341,120 (1) 

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    3,341,120 (1)
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐      
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.2% (2)
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    OO

     

    FOOTNOTES

     

    (1) The shares of common stock reported in this row are held by Master Fund. Soleus Capital is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. SCG is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

     

    (2) This percentage is calculated based upon 64,677,145 shares of Common Stock outstanding as of May 3, 2024, as reported in the Form 10-Q.

     

    3

     

     

    CUSIP No. 880881107  

     

    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
    Soleus Capital Group, LLC
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ☐

    (b) ☐

    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    3,341,120 (1)
    7 SOLE DISPOSITIVE POWER
    0
    8 SHARED DISPOSITIVE POWER
    3,341,120 (1) 

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    3,341,120 (1)
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐      
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.2% (2)
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    OO

     

    FOOTNOTES

     

    (1) The shares of common stock reported in this row are held by Master Fund. Soleus Capital is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. SCG is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

     

    (2) This percentage is calculated based upon 64,677,145 shares of Common Stock outstanding as of May 3, 2024, as reported in the Form 10-Q.

     

    4

     

     

    CUSIP No. 880881107  

     

    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
    Guy Levy
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ☐

    (b) ☐

    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    3,341,120 (1)
    7 SOLE DISPOSITIVE POWER
    0
    8 SHARED DISPOSITIVE POWER
    3,341,120 (1) 

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    3,341,120 (1)
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐      
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.2% (2)
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    IN

     

    FOOTNOTES

     

    (1) The shares of common stock reported in this row are held by Master Fund. Soleus Capital is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. SCG is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

     

    (2) This percentage is calculated based upon 64,677,145 shares of Common Stock outstanding as of May 3, 2024, as reported in the Form 10-Q.

     

    5

     

     

    Item 1.

     

      (a) Name of Issuer
        Terns Pharmaceuticals, Inc.

     

      (b) Address of Issuer’s Principal Executive Offices
        1065 East Hillsdale Blvd., Suite 100
    Foster City, CA 94404

     

    Item 2.

     

      (a) Name of Person(s) Filing
       

    Soleus Capital Master Fund, L.P.

    Soleus Capital, LLC

    Soleus Capital Group, LLC

    Guy Levy

     

      (b) Address of Principal Business Office or, if none, Residence
       

    Soleus Capital Master Fund, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital Group, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Guy Levy

    c/o Soleus Capital Management, L.P

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

      (c) Citizenship
       

    Soleus Capital Master Fund, L.P. – Cayman Islands

    Soleus Capital, LLC – Delaware

    Soleus Capital Group, LLC - Delaware

    Guy Levy – United States

     

      (d) Title of Class of Securities
        Common Stock, $0.0001 par value per share

     

      (e) CUSIP Number
        880881107

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    6

     

     

      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. ☐78c).
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).
           
      (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4. Ownership.

     

    Reference is made to Items 5 – 11 on the preceding pages of this Schedule 13G.

     

    Master Fund held, as of the close of business on June 6, 2024, an aggregate of 3,341,120 shares of the common stock of the Issuer. As the general partner of Master Fund, Soleus Capital may be deemed to have shared power to vote or to direct the vote and to dispose or to direct the disposition of the shares held by Master Fund. As the sole managing member of Soleus Capital, SCG may be deemed to have shared power to vote or to direct the vote and to dispose or to direct the disposition of the shares held by Master Fund. As the sole managing member of SCG, Mr. Guy Levy may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the Shares held by Master Fund.

     

    Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that Mr. Levy, Soleus Capital or SCG is the beneficial owner of the shares of the common stock of the Issuer referred to herein for purposes of Section 13(d) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed, except to the extent of their respective pecuniary interests therein.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification
     

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose, or with the effect, of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    7

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Date: June 7, 2024 Soleus Capital Master Fund, L.P.
         
      By: Soleus Capital, LLC, its General Partner
         
      By: Soleus Capital Group, LLC, its Managing Manager
         
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
         
    Date: June 7, 2024 Soleus Capital, LLC
         
      By: Soleus Capital Group, LLC, its Managing Manager
         
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
         
    Date: June 7, 2024 Soleus Capital Group, LLC
         
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title: Managing Member
         
    Date: June 7, 2024 /s/ Guy Levy
      Name: Guy Levy

     

    Footnotes:  
       
    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    8

     

     

    EXHIBIT A

    JOINT FILING AGREEMENT

     

    Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, and Guy Levy, an individual, hereby agree to file jointly the statement on Schedule 13G to which this Joint Filing Agreement is attached, and any amendments thereto which may be deemed necessary, pursuant to Regulation 13D-G under the Securities Exchange Act of 1934, as amended.

     

    It is understood and agreed that each of the parties hereto is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein, but such party is not responsible for the completeness or accuracy of information concerning the other party unless such party knows or has reason to believe that such information is inaccurate.

     

    It is understood and agreed that a copy of this Agreement shall be attached as an exhibit to the statement on Schedule 13G, and any amendments hereto, filed on behalf of each of the parties hereto.

     

    Date: June 7, 2024 Soleus Capital Master Fund, L.P.
         
      By: Soleus Capital, LLC, its General Partner
         
      By: Soleus Capital Group, LLC, its Managing Manager
         
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
         
    Date: June 7, 2024 Soleus Capital, LLC
         
      By: Soleus Capital Group, LLC, its Managing Manager
         
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
         
    Date: June 7, 2024 Soleus Capital Group, LLC
         
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title: Managing Member
         
    Date: June 7, 2024 /s/ Guy Levy
      Name: Guy Levy

     

     

    9

     

     

    Get the next $TERN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TERN

    DatePrice TargetRatingAnalyst
    2/9/2026$58.00Outperform
    Leerink Partners
    11/4/2025$20.00Neutral → Buy
    H.C. Wainwright
    11/3/2025Mkt Perform → Outperform
    William Blair
    10/15/2025$20.00Buy
    Truist
    9/17/2025$15.00Overweight
    Barclays
    9/4/2025Neutral
    H.C. Wainwright
    2/28/2025Mkt Perform
    William Blair
    10/31/2024$82.00Outperform
    Oppenheimer
    More analyst ratings

    $TERN
    SEC Filings

    View All

    SEC Form 8-K filed by Terns Pharmaceuticals Inc.

    8-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)

    1/22/26 4:07:43 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)

    1/9/26 4:05:23 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Terns Pharmaceuticals Inc.

    8-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)

    12/11/25 7:45:19 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

    FOSTER CITY, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that it has granted as of February 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Terns. The Company granted options to purchase 113,500 shares, in the aggregate, of Terns common stock to the new employees

    2/2/26 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

    CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL data by 2H26, and initiation of 2L+ pivotal trial in late 2026/early 2027 TERN-701 was granted U.S. FDA Fast Track designation for the treatment of CML in Q4 2025 Year-end 2025 unaudited cash, cash equivalents and marketable securities of approximately $1.0 billion, expected to provide runway into 2031 FOSTER CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announ

    1/7/26 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

    FOSTER CITY, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that it has granted as of January 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Terns. The Company granted options to purchase 312,000 shares, in the aggregate, of Terns common stock to the new employees.

    1/2/26 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Terns Pharmaceuticals with a new price target

    Leerink Partners initiated coverage of Terns Pharmaceuticals with a rating of Outperform and set a new price target of $58.00

    2/9/26 6:54:14 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Terns Pharmaceuticals from Neutral to Buy and set a new price target of $20.00

    11/4/25 8:12:25 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals upgraded by William Blair

    William Blair upgraded Terns Pharmaceuticals from Mkt Perform to Outperform

    11/3/25 10:27:19 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Gengos Andrew bought $39,283 worth of shares (10,000 units at $3.93), increasing direct ownership by 67% to 25,000 units (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    6/30/25 5:38:10 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Burroughs Amy L. bought $90,230 worth of shares (23,314 units at $3.87), increasing direct ownership by 98% to 47,083 units (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    6/25/25 6:08:58 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Gengos Andrew bought $57,082 worth of shares (15,000 units at $3.81) (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    6/16/25 6:05:21 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Turner Heather D

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    2/2/26 6:07:42 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Tripuraneni Radhika

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    2/2/26 6:07:17 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Azelby Robert

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    2/2/26 6:06:50 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Leadership Updates

    Live Leadership Updates

    View All

    Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

    FOSTER CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Andrew Gengos as chief financial officer, effective immediately. "We are delighted to have Andrew join the Terns' team as our new chief financial officer, confident his extensive experience and proven track record of financial leadership will be instrumental in driving our growth. We look forward to Andrew's contributions as we continue to advance our mission to transfor

    2/24/25 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

    FOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Robert Azelby, a seasoned biotechnology executive and board director, to the Company's Board of Directors, effective immediately. In conjunction with Mr. Azelby's appointment, Carl Gordon is stepping down from the Board of Directors following more than seven years of service. "I am thrilled to welcome Bob to the Terns Board as he brings extensive strategic and operationa

    2/20/25 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

    FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc., to the Company's Board of Directors, effective immediately. In conjunction with Ms. Turner's appointment, Ann E. Taylor, M.D., is stepping down from the Board of Directors following more than three years of service. "It is my pleasure to welcome Heather to the Terns Board, and I am confide

    11/18/24 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Financials

    Live finance-specific insights

    View All

    Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

    64% MMR achievement by 24 weeks across all efficacy evaluable patients  75% MMR achievement by 24 weeks in efficacy evaluable patients at doses >320mg QD Encouraging safety/tolerability profile maintained with longer duration of treatment Company to host investor update call today at 4:30pm ET FOSTER CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (NASDAQ:TERN), a clinical-stage oncology company, today announced that updated and expanded data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in patients with previously treated chronic myeloid leukemia (CML) are being presented today a

    12/8/25 2:45:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

    Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract  Upcoming ASH oral presentation to feature expanded and updated dataset from CARDINAL trial Cash, cash equivalents and marketable securities of $295 million, expected to provide runway into 2028 FOSTER CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today reported financial results for the third quarter ended September 30, 2025, and provided corporate updates. "We're thrilled with the positive momentum of the CARDINAL program generated by the unprecedented Phase 1

    11/10/25 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

    Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host investor update call on December 8th at 4:30pm ET FOSTER CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (NASDAQ:TERN), a clinical stage oncology company, today announced that data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in participants with previously treated chronic myeloid leukemia (CML) has been selected for oral presentation on December 8, 2025 at the 67th American Society of Hema

    11/3/25 9:05:00 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/15/24 10:35:07 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/14/24 7:00:26 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/14/24 5:51:38 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care